ArticlePloS one2018
Cognition among individuals along a spectrum of increased risk for Parkinson's disease.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2022Pooled it
- Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.Translational neurodegeneration · 2022Pooled it
- Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.Neurology · 2023Trial
- Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder.Annals of neurology · 2025Article
- AskBeacon-performing genomic data exchange and analytics with natural language.Bioinformatics (Oxford, England) · 2025Article
- Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.Movement disorders clinical practice · 2023Article
- Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study.NPJ Parkinson's disease · 2023Article
- Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.Current neurology and neuroscience reports · 2023Review
- Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease.Neurology · 2023Article
- Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study.Journal of Parkinson's disease · 2023Article
- Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson's disease.Journal of neurology · 2022Article
- Dream Content Predicts Motor and Cognitive Decline in Parkinson's Disease.Movement disorders clinical practice · 2021Article
- Parkinson disease-associated cognitive impairment.Nature reviews. Disease primers · 2021Review
- Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder.Annals of clinical and translational neurology · 2021Observational
- Cognitive Impairment in Genetic Parkinson's Disease.Parkinson's disease · 2021Review
- Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.The Lancet. Neurology · 2020Observational
- A Multicenter Preclinical MRI Study: Definition of Rat Brain Relaxometry Reference Maps.Frontiers in neuroinformatics · 2020Article
- Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's disease.Journal of clinical and experimental neuropsychology · 2019Article
- The Neuropsychiatry of Parkinson Disease: A Perfect Storm.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2019Review
- Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.Brain sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 16 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral characteristics associated with increased risk for Parkinson's disease (PD) have been identified, including specific genotypes and various non-motor symptoms. Characterizing non-motor features, such as cognitive abilities, among individuals considered at-risk for PD is essential to improving prediction of future neurodegeneration.
methodsParticipants belonging to the following cohorts of the Parkinson Progression Markers Initiative (PPMI) study were included: de novo PD with dopamine transporter binding deficit (n = 423), idiopathic REM sleep behavior disorder (RBD, n = 39), hyposmia (n = 26) and non-PD mutation carrier (NMC; Leucine-rich repeat kinase 2 (LRRK2) G2019S (n = 88) and glucocerebrosidase (GBA) gene (n = 38) mutations)). Inclusion criteria enriched the RBD and hyposmia cohorts, but not the NMC cohort, with individuals with dopamine transporter binding deficit. Baseline neuropsychological performance was compared, and analyses were adjusted for age, sex, education, and depression.
resultsThe RBD cohort performed significantly worse than the hyposmia and NMC cohorts on Symbol Digit Modality Test (mean (SD) 32.4 (9.16) vs. 41.8 (9.98), p = 0.002 and vs. 45.2 (10.9), p<0.001) and Judgment of Line Orientation (11.3 (2.36) vs.12.9 (1.87), p = 0.004 and vs. 12.9 (1.87), p<0.001). The RBD cohort also performed worse than the hyposmia cohort on the Montreal Cognitive Assessment (25.5 (4.13) vs. 27.3 (1.71), p = 0.02). Hyposmics did not differ from PD or NMC cohorts on any cognitive test score.
conclusionAmong individuals across a spectrum of risk for PD, cognitive function is worse among those with the characteristic most strongly associated with future risk of PD or dementia with Lewy bodies, namely RBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.